Invitae (NYSE: NVTA) is one of 21 publicly-traded companies in the “Medical laboratories” industry, but how does it contrast to its rivals? We will compare Invitae to related companies based on the strength of its institutional ownership, dividends, earnings, analyst recommendations, profitability, risk and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Invitae and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invitae 0 0 4 0 3.00
Invitae Competitors 109 459 537 18 2.41

Invitae currently has a consensus target price of $11.00, suggesting a potential upside of 96.43%. As a group, “Medical laboratories” companies have a potential upside of 10.80%. Given Invitae’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Invitae is more favorable than its rivals.

Insider and Institutional Ownership

71.4% of Invitae shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are owned by institutional investors. 8.7% of Invitae shares are owned by insiders. Comparatively, 18.4% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Invitae and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Invitae $68.22 million -$123.38 million -2.11
Invitae Competitors $1.13 billion $76.65 million 212.80

Invitae’s rivals have higher revenue and earnings than Invitae. Invitae is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Invitae and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Invitae -180.85% -124.43% -68.92%
Invitae Competitors -118.73% -181.84% -42.80%

Volatility and Risk

Invitae has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Invitae’s rivals have a beta of 1.24, suggesting that their average share price is 24% more volatile than the S&P 500.


Invitae rivals beat Invitae on 8 of the 13 factors compared.

About Invitae

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.

Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with's FREE daily email newsletter.